ArticleFrontiers in oncology2025
Intravoxel incoherent motion-based habitat imaging for the prediction of immunohistochemistry in patients with breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis.Radiology and oncology · 2026Article
- Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study.BMC medical imaging · 2026Article
- MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the value of intravoxel incoherent motion (IVIM)-based habitat imaging in predicting immunohistochemistry in patients with breast cancer. Methods: 299 patients with suspected breast cancer were randomly assigned to a training set of 210 individuals and a test set of 89 individuals. A series of models was constructed for human epidermal growth factor receptor 2 (HER2)/Ki-67/hormone receptors (HR)/lymph node metastasis (LNM) prediction, including the whole-tumor model, habitat model, conventional MRI features (CF) model and hybrid model (incorporating habitats features and CF). The performance of various models was evaluated with the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA). P (two-tailed) < 0.05 was considered statistically significant. Results: On the test cohort, for HER2/HR/LNM, the habitats model achieved the highest AUC values of 0.692/0.651/0.722, higher than those of the whole-tumor model (AUC = 0.591/0.599/0.609) and the CF model (AUC = 0.598/0.603/0.608). For Ki-67, the CF model achieved a highest AUC of 0.746. The hybrid model achieved AUC values of 0.706/0.762/0.668/0.728 for HER2/Ki67/HR/LNM. DeLong test showed a significant difference between habitats model and the whole-tumor model for LNM ( Conclusion: While habitat features can provide richer biological information, the models combining habitats and CF obtained more accurate results than other models, making them promising candidates for clinical application in breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.